onsultation Paper
Implementation 17 4. Guidelines on the management of interest rate risk and on the assessment and monitoring of credit spread risk, arising from non-trading book activities 18 4.1 General provisions 18 4.2 Identification and management of IRRBB 20
Download onsultation Paper
Information
Domain:
Source:
Link to this page:
Documents from same domain
Joint Committee Final Report on Big Data - …
www.eba.europa.eu4 1. Overview 1. One of the tasks of the European Banking Authority (EBA), the European Securities and Markets Authority (ESMA) and the European Insurance and
RISK ASSESSMENT OF THE EUROPEAN BANKING …
www.eba.europa.euRISK ASSESSMENT OF THE EUROPEAN BANKING SYSTEM 3 Contents Abbreviations 7 Executive summary 8 Introduction 10 1. Macroeconomic environment and …
EBA FINANCIAL EDUCATION REPORT 2017/18
www.eba.europa.euEBA FINANCIAL EDUCATION REPORT 2017/18 . 3 . Executive summary . One of the mandates conferred on the European Banking Authority (EBA) is to ‘review and
BoS 2018 xx CP on Draft GL on disclosure of non …
www.eba.europa.eu6 (i) The Council invites the EBA to issue guidelines on NPL management consistent with the ECB-SSM "Guidance to banks on Non-Performing Loans" (SSM Guidance).
Call for expression of interest regarding the …
www.eba.europa.euCALL FOR EXPRESSION OF INTEREST REGARDING THE SETTING UP OF THE EBA’S BANKING STAKEHOLDER GROUP . 1 12 March 2018 . Call for expression of interest regarding
Final report
www.eba.europa.euFINAL REPORT ON THE GUIDELINES ON DISCLOSURE REQUIREMENTS UNDER PART EIGHT OF REGULATION (EU) NO 575/2013 . 2 . Contents . 1. Executive summary 5
EBA REPORT
www.eba.europa.euREMUNERATION BENCHMARKING AND HIGH EARNERS REPORT (DATA AS OF END 2016) 6 . Executive summary . Under Directive 2013/36/EU (CRD IV), the European Banking Authority (EBA) is required to
EBA/CP/2018/11 22/06/2018
www.eba.europa.euCONSULTATION PAPER ON GUIDELINES ON OUTSOURCING . 2 . Contents Responding to this consultation 4 Draft Consultation Paper on Guidelines …
EBA/GL/2017/12 26 September 2017
www.eba.europa.euEBA/GL/2017/12 26 September 2017 . Final report Joint ESMA and EBA Guidelines on the assessment of the suitability of members of the management body and key function holders under Directive 2013/36/EU and Directive 2014/65/EU . FINAL REPORT ON GUIDELINES ON THE ASSESSMENT OF THE SUITABILITY OF
Opinion of the European Banking Authority on preparations ...
www.eba.europa.euThis opinion is in line with the European Council guidelines. 11 . and the European . 8. Article 50 also allows the European Council, in agreement with the Member States, to extend this period. 9. See: HM Government, The United Kingdom’s exit from and new partnership with the European …
Related documents
Therapy Codes Update - Centers for Medicare & Medicaid ...
www.cms.govMay 26, 2020 · Implementation Date: MACs June 16, 2020 FISS - July 6, 2020 . Note: We revised this article to reflect a revised CR11791. The CR revisi on changed the implementation date for the MACs and we revised that date in the article. Also, we revised the CR release date, transmittal number, and the web address of the CR. All other information is the same.
onsultation Paper
www.eba.europa.euDraft Guidelines On policies and procedures in relation to compliance management and the role and responsibilities of the AML/CFT Compliance Officer under Article 8 and Chapter VI of Directive (EU) 2015/849 . ... for the implementation of the law, regulations and administrative provisions necessary to ...
Questions and answers to Stakeholders on the ...
www.ema.europa.euQuestions and answers to Stakeholders on the implementation of the Protocol on Ireland/Northern Ireland EMA/520875/2020 Page 2/11 information on medicinal products authorised in Northern Ireland recorded in Article 57 Database). The below guidance addresses the changes in article 57 database that will affect marketing authorisation holders. 2.1.
Implementation Process Article 5(3) Nitrosamine
www.ema.europa.euQ&A for the implementation of the Article 5(3) referral. As a result of the call for review to MAHs for authorised medicines or for new MAAs, the MAH/applicant should forthwith inform CAs if N-nitrosamines are identified, irrespective of the amount detected.